APA (7th ed.) Citation

Karol, S. E., Alexander, T. B., Budhraja, A., Pounds, S. B., Canavera, K., Wang, L., . . . Rubnitz, J. E. (2020). Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: A phase 1, dose-escalation study. The lancet oncology, 21(4), 551-560. https://doi.org/10.1016/S1470-2045(20)30060-7

Chicago Style (17th ed.) Citation

Karol, Seth E., et al. "Venetoclax in Combination with Cytarabine with or Without Idarubicin in Children with Relapsed or Refractory Acute Myeloid Leukaemia: A Phase 1, Dose-escalation Study." The Lancet Oncology 21, no. 4 (2020): 551-560. https://doi.org/10.1016/S1470-2045(20)30060-7.

MLA (9th ed.) Citation

Karol, Seth E., et al. "Venetoclax in Combination with Cytarabine with or Without Idarubicin in Children with Relapsed or Refractory Acute Myeloid Leukaemia: A Phase 1, Dose-escalation Study." The Lancet Oncology, vol. 21, no. 4, 2020, pp. 551-560, https://doi.org/10.1016/S1470-2045(20)30060-7.